Who
Julie Krop
Director
Company insider
Files Form 4 as: Director, Aquestive Therapeutics; Chief Medical Officer, DiaMedica Therapeutics; Chief Medical Officer, Amag Pharmaceuticals.
In numbers
- Trades disclosed
- 45
- Buys
- 1
- Sells
- 4
- Bought
- $99K
- Sold
- $518K
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 1 Jun 2015
- Last trade
- 23 Jun 2026
- Last filed
- 24 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jun 2026filed 24 Jun 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code M | $18K25,000 at $0.7132 | filing |
| 23 Jun 2026filed 24 Jun 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $125K25,000 at $5.02 | filing |
| 23 Jun 2026filed 24 Jun 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 23 Jun 2026filed 24 Jun 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 23 Jun 2026filed 24 Jun 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code M | $18K25,000 at $0.71 | filing |
| 23 Jun 2026filed 24 Jun 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $126K25,000 at $5.02 | filing |
| 10 Jun 2026filed 12 Jun 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —50,500 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —50,500 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,500 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,500 at $0.00 | filing |
| 11 Aug 2025filed 3 Nov 2025 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
| 11 Jun 2025filed 12 Jun 2025 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $143K42,000 at $3.41 | filing |
| 20 Jun 2024filed 21 Jun 2024 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 21 Jun 2023filed 23 Jun 2023 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 22 Jun 2022filed 24 Jun 2022 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 15 Jun 2021filed 17 Jun 2021 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 11 Mar 2021filed 15 Mar 2021 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —28,500 at $0.00 | filing |
| 2 Mar 2020filed 4 Mar 2020 | Amag Pharmaceuticals | SEC FORM 4 Code F | $10K1,333 at $7.75 | filing |
| 25 Feb 2020filed 25 Feb 2020 | Amag Pharmaceuticals | SEC FORM 4 Code F | $10K1,155 at $8.84 | filing |
| 23 Feb 2020filed 25 Feb 2020 | Amag Pharmaceuticals | SEC FORM 4 Code F | $8,237867 at $9.50 | filing |
News
Aquestive Therapeutics Wins FDA Acceptance Of Anaphylm NDA ResubmissionAQST · rttnews.com · 15 Oct 2026Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal FilmAQST · manilatimes.net · 14 Oct 2026Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock DropAQST · prnewswire.com · 7 Oct 2026
0 headlines in the last 90 days name Julie Krop; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.